What are they doing?, page-25

Sgsundy,

Since we're dealing with "drugs" that are attenuators - that essentially function as "weaker chelators" means they primarily focus on "rogue" metallic ions. Therefore, their greatest chance of being effective is dealing with diseases/situations in which the metallic ions play pivotal roles. If you read any of the posts, you'd see that they are basically identifying mechanisms where these ions are pivotal. Interestingly, there is a lot of similarity in addressing many of the problems because they are affecting the function (or malfunction) of the mitochondria.

I admit, reading some of the posts is a bit deep, festooned with challenging terminology. For that reason I'm constantly amassing a glossary of new terms when "de-coding" these posts, but the common denominator are the metallic ions triggering adverse events. PBT434, PBT2, etc. address these events. That's why I see this "poster's list" as potentially relevant.